CD178 (CD95-ligand) is expressed on several tumor cells and likely influences the interaction of the tumor with the host immune system. However, little is known about the mechanisms that regulate its expression on the cell surface. We have evaluated the ability of various compounds and cytokines to regulate cell surface expression and release of soluble CD178 in various carcinoma cell lines. Vitamin E succinate (VES) and retinoic acid (RA) were found to reduce CD178 surface expression, whereas interferon-␥ stimulated a slight upregulation. At 48 h, the regulation of surface CD178 by VES and RA arose from a small decrease in CD178 mRNA and to a greater extent due to an increase in the release of soluble CD178; the latter was blocked by addition of a metalloproteinase inhibitor. Accordingly, VES and RA treatment diminished the ability of tumor cells to kill CD95-sensitive cells and this effect was markedly reduced by the presence of a metalloproteinase inhibitor. Our results indicate that, in vitro, CD178 expression on the cell surface of tumor cells can be regulated by agents that alter both expression and release of the ligand. In vivo, such treatments may play an important role in the outcome of tumor sensitivity or resistance to host immune mechanisms.
INTRODUCTION
Cancer cells express a variety of surface molecules that should be recognized as non-self by the immune system. However, tumors often fail to provoke a significant immune response. Several mechanisms may contribute to this failure, including downregulation of MHC and costimulatory molecules, defective antigen processing, and production of immunosuppressive cytokines [1, 2] . More recently CD95(APO-1/Fas) ligand (CD178), one of the TNF family members, has been proposed to be involved in maintaining a state of tumor immune privilege. While CD178 expression has been reported in a variety of tumor cells [e.g., [3] [4] [5] [6] , its role in induction of apoptosis of tumor-infiltrating lymphocytes (TIL) remains controversial (for review see Ref. [7] ). Many studies have reported that CD178 expression on tumor cells enables these cells to induce apoptosis in TIL, which express the Fas receptor (e.g., [4, 6] ). However, in contrast to these findings, transfection of murine tumors with CD178 cDNA caused their rejection by syngeneic host [8, 9] . Studies have been further complicated due to questions about some of the reagents used to follow expression of CD178 on these cells [10, 11] . Very recently it has been described that none of multiple colon cancer lines was able to induce apoptosis in Fas-sensitive target cells; this was attributed to the lack of CD178 surface expression, despite the expression of mRNA and CD178 protein in the cancer cells [10] . In addition, it has been proposed that CD178 expressed on T cells as a result of activation after recognition of tumor cells might cause "suicide" or "fratricide" [11] .
In addition to these uncertainties, little is known about mechanisms that regulate expression of CD178 mRNA and protein (intracellular and cell surface) and the subsequent release of sCD178 in tumor cells. Release of CD178 from either tumor or T cells might be expected to alter the outcome of T-cell apoptosis. Knowledge about the connection between intracellular CD178, cell surface CD178, and released sCD178 will help in the understanding of how CD178 on different cells might influence host-tumor interactions. Therefore, we have investigated various compounds and cytokines that have previously been reported to influence the growth and invasiveness of cancer cells for their ability to modulate CD178 expression. We have followed the effects of several of these agents on CD178 at the levels of mRNA, cell surface expression, and re- 1 To whom correspondence and reprint requests should be addressed at Department of Immunology and Inflammation, K14-04, Bristol Myers Squibb, PRI, P.O. Box 4000, Princeton, NJ 08543. Fax: 609 252 6058. E-mail: kienerp@bms.com.
lease of soluble ligand. The results show that several of these agents modulate CD178 in the tumor cells and thus may play an important role in determining the interaction of the tumor with its local environment. This in turn may be a significant determining factor in the response of the tumor to host immune surveillance.
MATERIAL AND METHODS
Cell preparation and culture. Fas-sensitive Jurkat cells and human carcinoma cell lines A 2780 (ovarian), Colo 205 (colon), HT 29 (colon), LNCaP (prostate), LS 174T (colon), LX 1 (lung), and PC 3 (prostate) were cultured in RPMI 1640 medium supplemented with 10% heat-inactivated FCS and 1% penicillin/streptomycin. HCT 116 (colon) and SKBR 3 (breast) cell lines were grown in McCoy's medium with the same supplements. Where indicated, tumor cells were fixed by incubation for 1 h in 200 l of PBS containing 2% formaldehyde/well at room temperature. Plates were then washed three times with PBS and used for coculture experiments. Tumor cells fixed this way showed no metabolic activity when assayed with Alamar blue. When supernatants were assayed for sCD178, 5 ϫ 10 5 tumor cells were grown in 24-well plates in RPMI containing the described supplements. After 48 h the medium was exchanged to RPMI containing 1% FCS, compounds were added as indicated, and cells were incubated for another 24 or 48 h before the supernatants were harvested.
Reagents. Goat anti-mouse FITC conjugate was from Biosource International (Camarillo, CA). The anti-CD178 mAb clones 4H9 and 4A5 were from MBL, Nagoya, Japan. Rabbit anti CD178 Abs C20, and Q20 were from Santa Cruz Laboratories (Santa Cruz, CA) and rabbit anti-CD178 Ab-1 was from Oncogene Research Products (Boston, MA). Rat anti-mouse CD4 FITC conjugate were obtained from PharMingen (San Diego, CA); FITC-conjugated anti-CD178 mAb clone H11 was from Alexis (San Diego, CA). The recombinant sCD178 and the FasIg fusion protein were prepared and purified as previously described [12] . VES, trans-RA, and streptavidin-alkaline phosphatase conjugate were from Calbiochem-Novabiochem Corp. (La Jolla, CA); formaldehyde (methanol free) was from Polysciences, Inc. (Warrington, PA); Alamar blue was obtained from Biosource International. The MPI (N4-hydroxy-N1-[(1S)-2-(methylamino)-2-oxo-1-(phenylmethyl)ethyl]-2-(2-methylpropyl)-(2R)-butanediamide) was synthesized within Bristol-Myers Squibb as described in Ref. [13] . All other reagents were obtained from Sigma (St. Louis, MO).
Flow cytometry. For the FACS analysis of surface expression of CD178 on tumor cell lines, cells were washed once in PBS and 5 ϫ 10 5 cells were incubated at 4°C in 100 l staining buffer (PBS containing 10% FCS, 250 g /ml human IgG, and 0.1% azide) containing 10 g/ml H11 FITC conjugate or anti-mouse CD4 FITC conjugate, respectively. After incubation for 1 h on ice, cells were washed twice with PBS containing 0.1% azide and counterstained with PI to ensure that only live cells were evaluated. Alternatively, where indicated, 247-4 mAb and mouse IgG1 were used. After 1 h incubation, cells were washed twice with PBS-azide and incubated at 4°C for 30 min in 100 l of a 1:50 solution of goat anti-mouse-FITC conjugate in the respective staining buffer. Again, to ensure that only live cells were evaluated, cells were counterstained with PI and positive cells were gated out. Samples were analyzed on a FACScan (Becton Dickinson, Mountain View, CA) by monitoring for forward versus side scatter and FL1 and FL2, respectively.
RNA extraction. Extraction of mRNA from tumor cells was performed using the Fast Track 2.0 kit from Invitrogen (Carlsbad, CA) as instructed by the manufacturer.
Reverse trancriptase PCR. Complementary DNA (cDNA) was prepared using the SUPERSCRIPT preamplification system for firststrand cDNA synthesis (GIBCO BRL, Rockville, MD) using 3 g total RNA per sample. Aliquots of 5 l of the cDNA were then amplified with 44 l of PCR supermix high fidelity (GIBCO BRL) and 0.5 l of each primer (final concentration 0.5 M). For detection of human CD178 cDNA, the primers used for amplification were human CD178 sense primer corresponding to nucleotides 276 -293 (5Ј-TGA AGA AGA GAG GGA ACC-3Ј) and antisense primer complementary to nucleotides 659 -676 (5Ј-GTT GTT GCA AGA TTG ACC-3Ј). Primers for human ␤-actin (5Ј-GTG GGG CGC CCC AGG CAC CA-3Ј, nucleotides 144 -163, and 5Ј-CTC CTT AAT GTC ACG CAC GAT TC-3Ј, nucleotides 660 -683) served as control. After denaturation at 94°C for 5 min 35 PCR cycles were performed, each consisting of a denaturation step (94°C, 30 s), an annealing step (56°C, 30 s), and an elongation step (72°C, 1.5 min). The PCR products (expected size 401 base pairs (bp) for human CD178, 539 bp for human actin) were separated by electrophoresis on 1% agarose gel and visualized by staining with ethidium bromide.
Quantitative PCR. Total RNA was prepared from untreated and treated cells with Trizol (Life Technologies) and 2 g of RNA was used for first-strand cDNA synthesis using the SuperScript firststrand synthesis system (Life Technologies). Quantitative PCR was then performed using an ABI Prism 7700 Instrument with TaqMan Universal PCR Master Mix, ␤-actin, and FasL primers and probes. The conditions for the reaction were 2 min at 50°C, 10 min at 95°C, and 45 cycles: 20 s at 95°C, 20 s at 56°C, 30 s at 72°C. The sequences for the FasL primers were: forward, TGAGGAAAGTGGCCCATT-TAAC; reverse, GAAAGCAGGACAATTCCATAGGT; and for the FasL probe, vicTCCAACTCAAGGTCCATGCCTCTGGtamra. cDNA from activated T cells was used to construct the standard curve and to normalize primer efficiencies. Samples were analyzed in quadruplicate.
Northern blot hybridization. Samples of mRNA (2 g) were fractionated according to size in 3% formaldehyde-1.2% agarose gels and then transferred to nylon membranes. The membranes were prehybridized for 1 h in hybridization solution (Express hyb, Clonetech, Palo Alto, CA) at 65°C, and then hybridized for 2 h with a random primed [␣-
32 P]dCTP-labeled (Random Primed DNA Labeling Kit, Boehringer Mannheim, Indianapolis, IN) human CD178 cDNA fragment or a GAPDH cDNA fragment as a control (2 ϫ 10 6 cpm/ml). Membranes were washed twice in 2ϫ SSC with 0.05% SDS at room temperature and twice in 0.1ϫ SSC with 0.1% SDS at 65°C and exposed to X-ray film with intensifying screens at Ϫ70°C. The films were analyzed by densitometric scanning.
Western blot analysis. Tumor cells were isolated by dissociation with RPMI containing 5 mM EDTA and washed twice with PBS and the cell pellets resuspended at 5 ϫ 10 6 /100 l in PBS prior to the addition of 100 l of 2ϫ SDS Laemmli sample buffer containing ␤-mercaptoethanol [14] . Samples were heated at 95°C for 5 min and sheared by passage through a 25-gauge needle, prior to separation by SDS-PAGE on 4 -12% gradient acrylamide gels. Gels were then transferred to polyvinylidene difluoride membranes by Western blotting; the membranes were blocked with buffer containing 5% BSA and 10% nonfat dried milk and probed with anti-CD178 Ab C20 (1 g/ml), Q20 (1 g/ml), or Ab-1 (5 g/ml). The blots were visualized by probing with HRP-goat anti-rabbit IgG and chemiluminescence reagent (NEN Life Science Products, Inc., Boston, MA).
ELISA for sCD178. The assay was performed as previously described [16, 21] with minor modifications to increase sensitivity. Recombinant human FasL, produced as a soluble fusion protein comprising murine CD8 and the extracellular domain of human FasL [12] in CHO cells, was used as the standard in this assay. Briefly, 96-well plates were coated overnight at 4°C with 100 l/well of the capture Ab clone 4H9 at 1.0 g/ml. After incubation 100 l/well of 15% BSA was added and blocked for 2 h at 37°C. After washing four times with T-PBS, the standards and samples were added to the wells, and the plate was incubated for 2 h at 37°C. Medium that had not been conditioned by tumor cells was used as the negative control. After washing 10 times with T-PBS, 100 l of a solution of the biotinylated detection Ab clone 4A5 at 1 g/ml in 3% BSA was added and the plates were incubated for 2 h at 37°C. Plates were washed 10 times in T-PBS prior to the addition of streptavidin-alkaline phosphatase conjugate (1:2000 solution in 3% BSA); the plates were incubated for 1 h at 37°C and then washed 10 times with Trisbuffered saline. The plates were developed using the ELISA amplification system (Life Sciences, Inc., Bethesda, MA) according to the manufacturer's instructions. The absorbance was measured at 450 nm (reference 725 nm) in an ELISA plate reader. Concentrations of sCD178 in supernatants are expressed as mean Ϯ SE of quadruplicates from each treatment.
Assessment of T-cell viability in coculture. After coincubation of fixed carcinoma cells and 2 ϫ 10 4 Jurkat cells for 24 h, 25 l Alamar blue was added to each well and the plates were incubated for 12 h at 37°C. The absorbance was measured as the difference between that at 570 and 590 nm in an ELISA plate reader. Values are shown as percentage of T cells alone. Values are expressed as mean Ϯ SE of quadruplicates.
RESULTS

Expression of CD178 in Tumor Cell Lines
The expression of CD178 on the surface of the tumor cell lines A 2780, Colo 205, HCT 116, HT 29, LNCaP, LX 1, PC 3, and SKBR 3 was investigated by flow cytometry. Analysis of the staining of cells with the anti-CD178 mAb 247-4 compared with purified mouse IgG1, as an isotype control, revealed that the cells expressed CD178 at various densities ( Fig. 1 , column A). Similar results were seen with the anti CD178 FITC-conjugate clone H11 compared to control anti mouse CD4 FITC conjugate (Fig. 1, column B) . To determine whether the mAb H11 and 247.4 could compete in their binding to human CD178 on the cell surface, tumor cells were first preincubated with 100 l staining buffer containing 10 g/ml mAb 247.4 for 30 min on ice prior to the addition of the detecting FITC H11 mAb. Under these conditions, the addition of mAb 247.4 greatly reduced the binding of the H11-FITC conjugate (Fig. 1C) .
To confirm further the expression of CD178 protein in tumor cells lines, the tumor cell lysates (2.5 ϫ 10 7 / ml) were analyzed by Western blot analysis with different anti-CD178 Abs. Extracts from equal cell numbers were loaded in each well. With both C20 and Q20 Abs a doublet of protein bands centered around 38 kDa corresponding to CD178 were detected in all of the cell lines and the positive control (Hut 78 or HL 60 cells), but with differing levels of expression (Fig. 2A) ; similar results were seen with the anti CD178 Ab, Ab-1 (data not shown). Additionally, in some cells the Q20 Ab detected a band of about 43 kDa, probably a form of CD178 with different glycosylation.
The expression of CD178 mRNA was also evaluated using RT-PCR. Each of the tumor cell lines expressed mRNA for CD178 as revealed by the expected products of 401 bp (Fig. 2B ), again to differing extents. No products were obtained when the PCR analysis was performed under the conditions described above, but using tumor cell RNA instead of the respective reverse transcribed DNA, thus excluding contamination with genomic DNA (data not shown). The differences between the levels of expression of CD178 on the cell surface and that detected by Western blot (total protein) or RT-PCR (mRNA) may arise from the presence of intracellular pools of CD178 [16] or from the rapid release of surface CD178, since this can be cleaved from the cell surface by metalloproteinases [17, 18] . These enzymes might be differentially active in the different tumor cells.
Modulation of CD178 Expression of Tumor Cell Lines
Several different agents have been reported to influence the growth and invasiveness of tumor cells. Thus we investigated the effect of various compounds on CD178 surface expression by FACS analysis. The tumor cell lines were grown for 48 h at 37°C in 24-well plates, the medium was exchanged, the compounds were added, and the cells were cultured for another 48 h. Addition of 10 g/ml vitamin E succinate (VES) or retinoic acid (RA) to the culture medium resulted in a decrease in the expression of CD178 on the cell surface (Fig. 3) . The effect was most obvious in PC 3 cells (Fig.  3, panel 3) , but was also apparent in A 2780, Colo 205, and SKBR 3 cells. In agreement with previous reports [19, 20] , IFN-␥ (200 U/ml) induced an upregulation of CD178 expression, but in our experiments this was found to be relatively small (Fig. 3) . Ionomycin, phorbol-myristate acetate, and bombesin all caused changes in CD178 surface expression, but this varied depending on the tumor cell line (data not shown). No significant effect was observed on any of the cell lines following addition of epidermal growth factor, IL-10, or IL-12 (data not shown).
The effect of different concentrations of VES and RA on the surface expression of CD178 on PC 3 cells was investigated by FACS analysis. Staining of the cells with the anti-CD178 FITC conjugate H11 showed that both vitamins reduced the surface expression of CD178 in a dose-dependent way; however, the loss of expression was greater with VES compared to a equivalent concentration of RA (Fig. 4) . Addition of 10 M MPI in parallel with the compounds reduced downregulation of CD178 surface expression (Fig. 4) . Similar results were also seen when the cells were stained with 247.4 mAb instead of H11 (data not shown). At 10 g/ml the vitamins had no significant effect on cell viability and growth; however, at concentrations above this both vitamins reduced the cell viability (data not shown).
To determine the effect of the two compounds on CD178 mRNA expression, a Northern blot analysis of CD178 in mRNA from tumor cell pellets was performed following incubation of PC 3 cells with 10 g/ml of each vitamin. Hybridization with 32 P-labeled probes consisting of the extracellular domain of human CD178 revealed two bands of about 2.3 and 1.4 kb. Treatment with vitamins for 48 h reduced the intensity of these bands (compared to GAPDH controls) but only about twofold; VES appeared to cause a slightly greater reduction than the corresponding concentration of RA (Figs. 5A and 5B) . A quantitative PCR analysis of CD178 mRNA (compared to ␤-actin controls) was also carried out on cells treated with 10 M VES or RA for 3 or 7 days. The results were similar to those of the Northern analysis in that after 3 days there was a small decrease in the level of CD178 mRNA following VES or RA treatment; however, the difference between the two treatments was not apparent. After 7 days, the levels found in treated cells appeared to be very slightly higher than that in untreated cells ( Table 1) .
The release of sCD178 from cells by shedding or production of a differentially spliced soluble form has previously been reported (e.g., [21] ). We observed low levels of spontaneous release of sCD178 from several of the cell lines after 24 or 48 h in culture (5 ϫ 10 5 cells/ well cultured as described under Materials and Methods). At 48 h the levels PC3 and SKBR3 were 5-10 pg/ml while those from A2780 and HCT116 were lower but still detectable (Ͻ2 pg/ml). Since the VES-and RA-induced changes on FACS expression were most apparent with PC3 cells (Fig. 3) , these were chosen for further study. To determine whether the changes in in 100 l PBS were lysed in an equal volume of 2ϫ sample buffer, separated by SDS-PAGE on 4 -12% polyacrylamide gels, and transferred to PVDF membranes. The membranes were blocked and then probed with anti-CD178 Abs followed by donkey anti-rabbit IgG-HRP conjugate. The blot is one experiment from a total of two. (B) RT-PCR analysis of CD178 mRNA expression. Expression was determined by analysis of 3 g mRNA isolates from each cell line. The mRNA-specific amplification products for CD178 and ␤-actin were separated by agarose gel electrophoresis and visualized by staining with ethidium bromide. Reactions without added cDNA did not yield products (not shown). cell surface expression mediated by VES and RA gave rise to changes in the release of sCD178, cells were cultured for 48 h in 24-well plates, the medium was exchanged to RPMI containing 1% FCS with the same supplements, the cells were then incubated in the presence or absence of the vitamins, and the levels of sCD178 released into the supernatants after 24 h and 48 h were determined by ELISA. After 24 h, both VES and RA increased the release of sCD178 significantly compared to untreated control cells (P Ͻ 0.01), but no significant difference between the release mediated by either of the vitamins was observed (P ϭ 0.73). In contrast, after 48 h of incubation, sCD178 release mediated by VES was significantly higher than that by RA (P Ͻ 0.01). Again, both agents gave rise to the release of sCD178 that was significantly (P Ͻ 0.01) elevated over untreated controls (Fig. 6A) . Addition of 10 M MPI prior to the addition of vitamins significantly (P Ͻ 0.01, as determined in a Mann-Whitney test) reduced the effect of both RA and VES (Fig. 6B) .
Coculture of CD178-Expressing Tumor Cells and Fas-Sensitive Jurkat Cells
In order to determine whether CD178 expression on coculture and thence on the amount of CD178 expression (Fig. 7A) . To verify that the observed induction of apoptosis was specifically due to the CD95/CD178 pathway, the experiment was performed in the presence or absence of neutralizing anti CD178 mAb clone 4H9. In a range 25,000 to 200,000 PC 3 cells addition of 10 g/ml of the mAb significantly (all P Ͻ 0.05, Student t test) reduced the killing of Jurkat cells (Fig. 7A) . Similar but less pronounced results were obtained by addition of 25 g/ml FasIg to the culture medium (data not shown).
To assess the functional significance of the VES/RAmediated downregulation of CD178 expression, the ability of the tumor cells to induce apoptosis after incubation with 5 and 10 g/ml of the vitamins was investigated. Both substances reduced the CD178-induced death of Jurkat cells in a concentration-dependent manner. In concurrence with the effect on surface CD178 expression, VES at 10 g/ml blocked tumor cell-induced apoptosis more effectively than did RA. The effect of addition of compounds was statistically significant (all P Ͻ 0.005 by Kruskal-Wallis test) at all cell concentrations. Furthermore, in the range 50,000 to 100,000 cells, when the differences between the two vitamin treatments were most obvious, both the difference of VES to RA and the difference between the two concentrations of each single substance were statistically significant (all P Ͻ 0.05 by Mann-Whitney test) (Fig. 7B) . Neither of the vitamins had a direct effect on tumor cell growth or viability (data not shown); thus the reduction in apoptosis in the treated samples was due to the reduction of CD178 expression on tumor cells and not due to a toxic effect of the compounds.
It was shown earlier that an MPI prevented the drug-induced downregulation of surface CD178 expression and release of sCD178, thus the effect of an MPI on the tumor cell-induced killing of Jurkat cells was evaluated. The MPI alone did not cause marked changes in T-cell survival in the cocultures (Fig. 7C ), but 10 M MPI added prior to the vitamins abrogated the reduction in killing of Jurkat cells caused by these vitamins. The effect of addition of compounds was statistically significant as determined using the KruskalWallis test (all P Ͻ 0.05).
DISCUSSION
Originally, expression of CD178 was thought to be restricted to activated T and NK cells, but subsequently its expression has been found in nonlymphoid cells such as stroma cells of the eye and Sertoli cells of the testis and neurons. The latter findings led to the suggestion that CD178 may be important for maintaining a state of immune suppression [22] . Subsequently, it has been suggested that tumor cells not only downregulate their expression and sensitivity of CD95 (e.g., [23, 24] ), but may also express CD178 as a mechanism of immune escape. In several studies expression of CD178 resulted in the elimination of TIL [4, 6] . Our results confirm the expression of CD178 to differing extents, on a variety of carcinoma cell lines, by FACS, Western blot, and RT-PCR analysis.
Induction of apoptosis in TIL by tumor cells has been proposed as enabling the tumors to protect themselves against immune effector cells. It has been shown that activated lymphocytes that accumulate in human tumors express Fas, and that apoptosis of lymphocytes in situ is a common characteristic in human tumors (e.g., [4, 6] ). However, despite an increasing number of reports confirming this hypothesis, this model of immune evasion by the tumor is still controversial. Unexpectedly, transfection of murine tumors with CD178 cDNA caused their rejection by syngeneic host [8, 25] . One interpretation is that locally expressed CD178 induces surrounding cells to produce IL-8 or other granulocyte chemoattractants [25] , and two recent studies have shown that recombinant sCD178 has chemotactic activity on human and mouse neutrophils [26, 27] . In addition, it is known that Fas signaling activates a caspase cascade, which eventually results in cleavage of interleukin-1␤ from its inactive to its active form. Once activated, interleukin-1␤ is a potent proinflammatory cytokine [11] . Nevertheless, the exact proinflammatory function of CD178 is still unclear. Very recently the notion of CD178 as a mediator of a "tumor counterattack hypothesis" has been critically addressed by several reports that question the functional consequence of CD178 expression of carcinoma cells in the host tumor interaction [10, 11] . The apoptosis of TIL observed in tumor samples was suggested to be due to suicidal or fratricidal coexpression of CD178 and CD95 on T cells following continuous activation.
In the studies reported here, we found that several carcinoma cells expressed functional cell surface CD178 that could induce apoptosis in Jurkat cells; this response was dependent on the number of tumor cells in the culture. To confirm that the observed apoptosis was due to the CD95/CD178 system, the coculture experiments were performed in the absence or presence of the neutralizing anti-CD178 mAb clone 4H9. Addition of the mAb markedly reduced induction of apoptosis showing that this was indeed through CD95/ CD178. Thus, while the precise role of CD178 on tumor cells in humans is still unclear, several of these cell lines do express functional CD178.
In addition to the uncertainty of the role of CD178, little is known about the mechanisms in tumor cells that regulate expression of CD178 mRNA, intracellular and surface expression of the protein, and the release of sCD178. Recently, it has been shown that IFN-␥ upregulates CD178 expression on tumor cells [28] , and the cytokine promotes cellular differentiation and partial or total reversion of the malignant phenotype in several tumor cell types [19] . However, since IFN-␥ has pleiotropic effects on many different cells it is not possible to directly relate the overall outcome of tumor growth to changes in the CD95/CD178 pathway. In agreement with the previous reports, we found that Note. The results were normalized to the PCR product for the mRNA for ␤-actin from the same sample.
FIG. 5. Modulation of CD178 mRNA. (A)
Northern blot analysis of vitamin-treated PC3 cells. Cells were grown for 48 h at 37°C in T 175 flasks. Then the medium was exchanged, the compounds, at 10 g/mL were added, and cells were incubated for another 48 h. mRNA was extracted and 2 g mRNA was separated on a 1.2% formaldehyde gel and then transferred to a nitrocellulose membrane. The blots were hybridized was performed using 32 IFN-␥ caused a small upregulation of CD178 expressed on the surface of tumor cells. In contrast, VES and RA caused a marked decrease in the level of CD178 surface expression in a variety of tumor cell lines. These vitamins induce morphological changes, modulate hematopoetic differentiation, and inhibit growth in tumor cells [29, 30] . In addition, RA inhibits activation-induced apoptosis in T-cell hybridomas and thymocytes via inhibition of expression of CD178 mRNA and cell surface protein [31, 32] . RA appears to regulate transcription of CD178 in lymphocytes by binding to a response element in the target gene [33] . In contrast to its effects on CD178, RA is reported to have no significant effect on CD95 expression [32] . There are few detailed reports of how these vitamins may effect the expression of CD178 on cells derived from solid tumors. Plates were incubated for 24 h, Alamar blue was added, and the plates were analyzed as described under Materials and Methods. T cells in wells without tumor cells served as positive control. (B) PC 3 cells were grown for 48 h on tissue culture plates, the culture medium was then exchanged, and the indicated concentrations of compounds were added to the cells and plates incubated for additional 48 h. After incubation, the tumor cells were fixed as described and Jurkat cells were added to each well. Plates were incubated for 24 h, Alamar blue was added, and plates were analyzed as described under Materials and Methods. Again, T cells without tumor cells served as control. (C) PC 3 cells were grown for 48 h on tissue culture plates. The culture medium was then exchanged and, where indicated, 10 g/ml VES and/or 10 M MPI was added to the cells and plates were incubated for additional 48 h. After incubation, the tumor cells were fixed as described and Jurkat cells were added to each well. Plates were incubated for 24 h, Alamar blue was then added, and the plates were analyzed as described under Materials and Methods. T cells in wells without tumor cells served as positive control. * Significant (P Ͻ 0.05) difference from controls.
To further characterize the effects of VES and RA on the expression of CD178 in tumor cells we focused on the tumor cell line PC 3, which expressed appreciable levels of CD178 and was also rather responsive to these compounds. Incubation of PC 3 cells for 48 -72 h in the presence of either VES or RA resulted in a small decrease of CD178 mRNA as detected by Northern blot and RT-PCR analysis and a significant decrease in the levels of cell surface CD178 as measured by FACS. These results on mRNA levels at after 48 h are in agreement with the data obtained in lymphocytes [32] , but contrast the results reported by Mueschen and co-workers [34] , who found that RA induced an increase of CD178 mRNA in Tera-2 cells after 24 h. They did not see any significant reduction of CD178 mRNA until Day 6 of incubation. Additionally, RA was found to have no effect on CD178 expression as determined by immuno-histochemistry [34] . In our experiments, treatment with vitamins for 7 days gave rise to a slight increase in the mRNA levels over the control cells as measured by quantitative PCR.
The are several reports indicating that sCD178 can be released from cells, although the role of this in the pathogenesis of several diseases is controversial in that it has been described as either apoptosis preventing [35, 18] or apoptosis inducing [21, 36, 37] . Since the effect of the treatment of the cells with these vitamins on mRNA levels was transient (slightly lower at 48 -72 h, slightly elevated at 7 days) and not marked, we investigated whether VES and RA influenced the release of sCD178. Over 24 -48 h both vitamins were found to induce the release of sCD178 from PC 3 cells and to a lesser extent from several of the other tumor cell lines (data not shown). Thus the vitamin-induced decrease in cell surface CD178 expression was matched by a corresponding increase of sCD178 in the cell supernatants, with a concomitant loss in the ability of the cells to induce apoptosis in Jurkat cells. Incubation of cells with VES in the presence of an MPI (that is able to block the activity of a CD178 sheddase or metalloproteinase) abrogated both the vitamin-mediated reduction of cell surface CD178 and the increase in the release of sCD178. This in turn resulted in the maintenance of the ability of the cells to induce apoptosis in Jurkat cells in coculture. These results showing that the MPI could largely abrogate the effect of the vitamins, suggests that, under the experimental conditions that we have used, the changes in CD178 cell surface expression are likely regulated more by shedding from the cell surface than at the level of mRNA. Thus, likely, the vitamins are inducing the activation or expression of one or more sheddase. However, since the enzyme(s) involved in the release of CD178 from the cell surface is not well defined, it is difficult to measure this directly.
In summary we have demonstrated that VES and RA modulate CD178 cell surface expression and this results in a decrease in CD178-induced apoptosis in T cells. Both compounds have been shown to inhibit cell proliferation and to induce apoptosis in a variety of cancer cells in vitro and in vivo [38 -41] . In addition in acute promyelocytic leukemia. RA has been reported to mediate apoptosis through TRAIL, another member of the TNF family [42] , thus illustrating the potential therapeutic importance of these mechanisms. Agents such as RA are currently used for the treatment of epithelial cancer and promyelocytic leukemia and are being evaluated as preventive and therapeutic agents for a variety of other human cancers [43, 44] . However, their detailed mechanisms of action are still not fully understood. The data reported here suggest that in part their activity may be based on the ability to alter cell surface CD178 expression and subsequent release in tumor cells and thereby influence the functional interplay between tumor cells and the immune system.
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